These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 421235)

  • 21. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
    Moyer JD; Handschumacher RE
    Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
    [No Abstract]   [Full Text] [Related]  

  • 22. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK; Inouye T; Goldin A; Stark GR
    Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
    Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
    Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
    Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM
    Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
    Roboz J; Suzuki R; Rose E
    J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
    Branfman AR; Bruni RJ; Merrill YN; Chadwick M; Strong JM; Ervin TJ
    J Chromatogr; 1980 May; 182(2):163-9. PubMed ID: 7380909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The binding of N-(phosphonacetyl)-L-aspartate to aspartate carbamoyltransferase of Escherichia coli.
    Volź KW; Krause KL; Lipscomb WN
    Biochem Biophys Res Commun; 1986 Apr; 136(2):822-6. PubMed ID: 3518720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
    Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
    Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C
    Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.
    Eldo J; Heng S; Kantrowitz ER
    Bioorg Med Chem Lett; 2007 Apr; 17(7):2086-90. PubMed ID: 17336518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-(Phosphonacetyl)-L-aspartate (PALA): current status.
    Rozencweig M; Abele R; Piccart M; Von Hoff DD; Muggia FM
    Recent Results Cancer Res; 1980; 74():72-7. PubMed ID: 7444151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient synthesis of fluorothiosparfosic acid analogues with potential antitumoral activity.
    Pfund E; Lequeux T; Masson S; Vazeux M; Cordi A; Pierre A; Serre V; Hervé G
    Bioorg Med Chem; 2005 Aug; 13(16):4921-8. PubMed ID: 15975800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
    Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
    Swyryd EA; Seaver SS; Stark GR
    J Biol Chem; 1974 Nov; 249(21):6945-50. PubMed ID: 4371054
    [No Abstract]   [Full Text] [Related]  

  • 35. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
    Stewart DJ; Leavens M; Friedman J; Benjamin RS; Moore EC; Bodey GP; Valdivieso M; Burgess MA; Wiseman C; Loo TL
    Cancer Res; 1980 Sep; 40(9):3163-6. PubMed ID: 7427934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
    Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract]   [Full Text] [Related]  

  • 37. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
    Laval M; Azou Y; Giorgi D; Rosset R
    Exp Cell Res; 1986 Apr; 163(2):381-95. PubMed ID: 2869965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
    Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
    Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of the interaction of N-(phosphonacetyl)-L-aspartate with the catalytic subunit of aspartate transcarbamoylase. A slow conformational change subsequent to binding.
    Cohen RE; Schachman HK
    J Biol Chem; 1986 Feb; 261(6):2623-31. PubMed ID: 3949739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.